Australia markets closed

Sirnaomics Ltd. (2257.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
6.090-0.070 (-1.14%)
At close: 04:08PM HKT
Full screen
Previous close6.160
Open6.160
Bid6.060 x N/A
Ask6.090 x N/A
Day's range6.000 - 6.180
52-week range5.640 - 59.000
Volume857,700
Avg. volume4,416,512
Market cap533.718M
Beta (5Y monthly)-0.43
PE ratio (TTM)N/A
EPS (TTM)-8.040
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est72.09
  • PR Newswire

    Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

    Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate (ODC) agent. The ODC demonstrated potent antitumor activity in multiple tumor cell lines and a pancreatic tumor model in mice. The work was published in the latest issue of Journal of Onc

  • PR Newswire

    Sirnaomics Announces 2023 Annual Results

    Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023 (the "Year").

  • PR Newswire

    Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference

    Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT (Oligonucleotide & mRNA Therapeutics) Congress, which took place in Bosto